Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • neskirimli
    Participant
    Post count: 7

    While reading through internet for TED treatments, I saw on the American Tyroid Association web page that there is a drug called Rituxan(Rituximab) using for nearly all kind of autoimmune diseases including Graves Ophtalmopathy.

    Anyone heard about that and/or used it?

    Thanks..

    Kimberly
    Keymaster
    Post count: 4294

    Hello – There have been some smaller studies with Rituximab for thyroid eye disease, although the results have been conflicting. Some have shown a benefit, while others have not. Here are links to a couple of published studies:

    (Note on links: if you click directly on the following links, you will need to use your browser’s “back” button to return to the boards after viewing, or you will have to log back in to the forum. As an alternative, you can right-click the link and open it in a new tab or new window)

    http://www.medpagetoday.com/MeetingCoverage/ATA/42340

    http://www.medscape.com/viewarticle/824745

    There is also a major study going on to test a new med for thyroid eye disease; you can find info here:

    http://graveseyediseasestudy.com/

    If you are interested in pursuing this option, an experienced ophthalmologist would be a good place to start. This site is for surgeons, but these doctors are usually familiar with thyroid eye disease:

    http://www.asoprs.org/custom/directory/?pageid=3657&showTitle=1

    Hope this helps!

    snelsen
    Participant
    Post count: 1909

    Yes. I did. No improvement, no change. I am aware that it is one of the treatments that docs hope might help severe TED. It is expensive, and you pretty much need to get in a study if that is any issue. And, of course, it has some concerning side effects.
    I was willing to try most things, none really helped, except prednisone to relieve the pressure on my optic nerve until I could have an OD.
    TED is hard.

Viewing 3 posts - 1 through 3 (of 3 total)
  • You must be logged in to reply to this topic.